China High Quality Benzyl Nicotinate Manufacturers – 99% Apixaban CAS 503612-47-3 – Baoran

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

Our eternal pursuits are the attitude of "regard the market, regard the custom, regard the science" as well as the theory of "quality the basic, believe in the 1st and management the advanced" for Glutaraldehyde, Phenacetin, Tetrahydro-2-Methylfuran;, Adhering to the business philosophy of 'customer first, forge ahead', we sincerely welcome clients from at home and abroad to cooperate with us.
China High Quality Benzyl Nicotinate Manufacturers – 99% Apixaban CAS 503612-47-3 – Baoran Detail:

Specification

ITEM

STANDARD

Appearance

White to off-white solid

Purity

≥ 99%

Application

On April 26, 2007, Bristol-Myers Squibb and Pfizer announced a joint development of the new oral anticoagulant apixaban owned by Bristol-Myers Squibb as an upgraded alternative to warfarin.
In May 2011, apixaban was the first to be approved for the prevention of venous thrombosis in adult patients undergoing elective hip or knee replacement surgery in 27 EU countries, Iceland and Norway.
On November 20, 2012, the European Commission approved ELIQUIS (apixaban) for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) with one or more risk factors.
The Canadian Food and Drug Administration, Japan, and the U.S. Food and Drug Administration subsequently approved ELIQUIS (apixaban) for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) with one or more risk factors.
On April 12, 2013, ELIQUIS (Apixaban), was officially announced on the market in China. Apixaban is a novel oral factor Xa inhibitor for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery. Its launch provides a safe and effective new option for anticoagulation after orthopaedic surgery in clinical practice, and brings good news to Chinese patients undergoing elective hip/knee replacement.
Clinical studies have confirmed that compared with 40 mg subcutaneous injection of enoxaparin once a day, 2.5 mg of ELIQUIS (Apixaban) orally twice a day is more effective in preventing venous thromboembolic events after hip or knee replacement surgery , and does not increase the risk of bleeding.

Packing & Storage

100g/500g/1kg/25kg or as request;
Stored at room temperature and airtight.


Product detail pictures:

China High Quality Benzyl Nicotinate Manufacturers –  99% Apixaban CAS 503612-47-3 – Baoran detail pictures


Related Product Guide:

With our leading technology also as our spirit of innovation,mutual cooperation, benefits and advancement, we'll build a prosperous future together with your esteemed organization for China High Quality Benzyl Nicotinate Manufacturers – 99% Apixaban CAS 503612-47-3 – Baoran, The product will supply to all over the world, such as: Belize, kazan, Bogota, With a fully integrated operation system, our company has won a good fame for our high quality goods, reasonable prices and good services. Meanwhile, we have established a strict quality management system conducted in material incoming, processing and delivery. Abiding by the principle of "Credit first and customer supremacy", we sincerely welcome clients from home and abroad to cooperate with us and advance together to create a brilliant future.
  • High production efficiency and good product quality, fast delivery and completed after-sale protection, a right choice, a best choice.
    5 Stars By Tina from Bandung - 2018.09.19 18:37
    The company's products very well, we have purchased and cooperated many times, fair price and assured quality, in short, this is a trustworthy company!
    5 Stars By Rosalind from Panama - 2017.03.08 14:45
    Write your message here and send it to us

    Related Products